AMAG Pharmaceuticals, Inc. (AMAG) Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ trimmed its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 5.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 157,400 shares of the specialty pharmaceutical company’s stock after selling 8,300 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.45% of AMAG Pharmaceuticals worth $2,904,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue raised its holdings in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 510 shares during the last quarter. Hartford Investment Management Co. bought a new position in shares of AMAG Pharmaceuticals in the third quarter valued at about $186,000. 361 Capital LLC bought a new position in shares of AMAG Pharmaceuticals in the third quarter valued at about $197,000. Finally, Aperio Group LLC bought a new position in shares of AMAG Pharmaceuticals in the third quarter valued at about $198,000.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at $14.35 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48. AMAG Pharmaceuticals, Inc. has a 12-month low of $11.93 and a 12-month high of $36.83.

A number of research analysts recently issued reports on AMAG shares. Piper Jaffray Companies started coverage on AMAG Pharmaceuticals in a report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price target for the company. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 24th. Morgan Stanley initiated coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They issued an “overweight” rating and a $26.00 price objective for the company. Deutsche Bank reiterated a “hold” rating and issued a $24.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have given a buy rating to the stock. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $24.00.

COPYRIGHT VIOLATION WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) Shares Sold by Skandinaviska Enskilda Banken AB publ” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://stocknewstimes.com/2017/12/06/amag-pharmaceuticals-inc-amag-shares-sold-by-skandinaviska-enskilda-banken-ab-publ.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply